Premium
Toxicity comparisons between two chemotherapy regimens as adjuvant or salvage treatment in nonseminomatous testicular cancer
Author(s) -
Weiss Raymond B.,
Stablein Donald M.,
Muggia Franco M.,
Einhorn Lawrence H.,
Golbey Robert B.,
Dewys William D.
Publication year - 1988
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(19880701)62:1<18::aid-cncr2820620105>3.0.co;2-q
Subject(s) - medicine , testicular cancer , bleomycin , vinblastine , chemotherapy , regimen , cyclophosphamide , toxicity , oncology , cancer , salvage therapy , adjuvant , cisplatin , surgery
The Testicular Cancer Intergroup Study was initiated to evaluate the efficacy of adjuvant chemotherapy in Stage II and salvage therapy in Stage I nonseminomatous testicular carcinoma. Chemotherapy regimens of cisplatin, vinblastine, and bleomycin (PVB) or the same drugs plus cyclophosphamide and dactinomycin (VAB) were used at institution or cooperative group preference. A comparison of the toxicities of these two regimens shows that VAB caused significantly more mucosal, dermatologic, and otologic toxicity than PVB, and PVB caused more leucopenia. Both regimens were equally effective in controlling cancer. Either regimen could be used as chemotherapy in testicular cancer, and the decision about which one to use could be based on their differences in toxicity and degree of patient convenience.